SELLAS Life Sciences Group, Inc. License Agreements
37 Contracts & Agreements
- License Agreement effective as of March 31, 2022 by and between SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics (Shanghai) Inc (Filed With SEC on May 12, 2022)
- Exclusive License Agreement by and among SELLAS, SLSG, and 3DMed, dated as of December 7, 2020 (Filed With SEC on January 28, 2021)
- First Amendment to Amended and Restated Exclusive License Agreement between SLSG Limited LLC and Memorial Sloan Kettering Cancer Center, effective as of September 29, 2020 (Filed With SEC on November 13, 2020)
- License Agreement made as of May 19, 2018 by and between the Registrant and 38th Street Suites LLC (Filed With SEC on May 24, 2018)
- Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc (Filed With SEC on September 11, 2017)
- LICENSE AND SUPPLY TRANSFER AGREEMENT (Filed With SEC on March 10, 2016)
- LICENSE AND SUPPLY AGREEMENT By and between MONOSOL RX, LLC, and (Filed With SEC on August 11, 2014)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 17, 2014)
- LICENSE AND DEVELOPMENT AGREEMENT (Filed With SEC on March 17, 2014)
- LICENSE AGREEMENT (Filed With SEC on May 9, 2013)
- AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on March 28, 2012)
- LICENSE AGREEMENT (Filed With SEC on March 28, 2012)
- Ex-10.30 Patent License Agreement (Invitrogen IP Holdings, Inc.) dated November 1, 2007 (Filed With SEC on February 1, 2008)
- EX-10.14 License Agreemnet, dated May 19,2004 (Filed With SEC on January 10, 2008)
- EX-10.13 Co-Exclusive License Agreement, to UMMS disclosure number 03-33 (Filed With SEC on January 10, 2008)
- EX-10.12 Exclusive License Agreement, to UMMS disclosure number 03-60 (Filed With SEC on January 10, 2008)
- EX-10.11 Exclusive License Agreement, to UMMS disclosure number 03-17 (Filed With SEC on January 10, 2008)
- EX-10.10 Amended and Restated Exclusive License Agreement (Filed With SEC on January 10, 2008)
- EX-10.9 Exclusive License Agreement, to UMMS disclosure number 02-01 (Filed With SEC on January 10, 2008)
- EX-10.8 Non-Exclusive License Agreement, to UMMS disclosure number 01-36 (Filed With SEC on January 10, 2008)
- EX-10.7 Exclusive License Agreement (No.: UMMC 06-08-03) (Filed With SEC on January 10, 2008)
- EX-10.6 Exclusive License Agreement (No.: UMMC 03-75-01) (Filed With SEC on January 10, 2008)
- EX-10.5 Exclusive License Agreement (No.: UMMC 03-68-02) (Filed With SEC on January 10, 2008)
- EX-10.4 Exclusive License Agreement (No.: UMMC 06-21-01) (Filed With SEC on January 10, 2008)
- EX-10.2 License Agreement, dated March 15, 2007 (Filed With SEC on January 10, 2008)
- Ex-10.14 License Agreement between CytRx Corporation, Imperial College Innovations and Imperial College of Science and Technology, dated May 20, 2004 (Filed With SEC on November 19, 2007)
- Ex-10.13 Exclusive License Agreement between CytRx Corporation and the University of Massachusetts Medical School (03-33) (Filed With SEC on November 19, 2007)
- Ex-10.12 Exclusive License Agreement between CytRx Corporation and the University of Massachusetts Medical School (03-60) (Filed With SEC on November 19, 2007)
- Ex-10.11 Exclusive license Agreement between CytRx Corporation and the University of Massachusetts Medical School ((03-17) (Filed With SEC on November 19, 2007)
- Ex-10.10 Amended and Restated Exclusive License Agreement between CytRx Corporation and the University of Massachusetts Medical School (03-05, 00-37, 01-31, 03-134, 93-09 and... (Filed With SEC on November 19, 2007)
- Ex-10.9 Exclusive License Agreement between CytRx Corporation and the University of Massachusetts Medical School (02-01) (Filed With SEC on November 19, 2007)
- Ex-10.8 Non-Exclusive License Agreement, between CytRx Corporation and the University of Massachusetts Medical School (01-36) (Filed With SEC on November 19, 2007)
- Ex-10.7 Non-Exclusive License Agreement (No.: UMMC 06-08-03) between the University of Massachusetts and RXi Pharmaceuticals Corporation (Filed With SEC on November 19, 2007)
- Ex-10.6 Exclusive License Agreement (No.: UMMC 03-75-01) between the University of Massachusetts and RXi Pharmaceuticals Corporation (Filed With SEC on November 19, 2007)
- Ex-10.5 Exclusive License Agreement (No.: UMMC 03-68-02) between the University of Massachusetts and RXi Pharmaceuticals Corporation (Filed With SEC on November 19, 2007)
- Ex-10.4 Exclusive License Agreement (No.: UMMC 06-21-01) between the University of Massachusetts and RXi Pharmaceuticals Corporation (Filed With SEC on November 19, 2007)
- Ex-10.2 License Agreement between Cold Spring Harbor Laboratory and RXi Pharmaceuticals Corporation (Filed With SEC on November 19, 2007)
